Business Context and Reporting Period
Company: Modular Medical, Inc. (MODD)
Filing Type: Form 8-K (Current Report)
Date of Report: September 22, 2025
Event: Entry into Material Definitive Agreements regarding warrant inducements and unregistered sales of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $3.7 million expected from the exercise of outstanding warrants.
- Transaction Costs: Newbridge Securities Corporation will receive a fixed fee of $400,000 plus up to $50,000 in expense reimbursements.
- Warrants Exercised:
- 2023 Warrants: 1,519,200 shares (Exercise price reduced to $0.68/share).
- 2025 Warrants: 3,975,428 shares (Exercise price reduced to $0.68/share).
- New Warrants Issued: Approximately 2,747,314 shares (50% of exercised warrants) at an exercise price of $0.84/share.
- Reference Price: $0.7611 (Nasdaq Official Closing Price on September 19, 2025).
Material Changes and Transaction Mechanics
The Company entered into inducement offer letters to modify the terms of existing warrants issued in 2023 and 2025. Key changes include:
- Price Reduction: The exercise price for the targeted warrants was reduced to $0.68 per share, representing a ~10% discount to the market price.
- Inducement: In exchange for the price reduction and exercise, holders received new warrants (New Warrants) with a 5-year term and an exercise price of $0.84 per share (~10% premium to market price).
- Liquidity: The New Warrants are unregistered, carry restrictive legends, and are not expected to have an active trading market.
- Cashless Exercise Option: If resale registration is not effective at the time of exercise, holders may elect a net share settlement instead of cash payment.
Outlook, Risks, and Management Commentary
- Closing Date: The transaction is expected to close on or about September 25, 2025.
- Future Activity: Management expects to enter into further Warrant Letters prior to the Closing Date, with final amounts to be disclosed later.
- Registration Status: Shares underlying the 2023 and 2025 warrants are registered on effective Form S-3 statements. The New Warrants are issued under Section 3(a)(9) and Rule 506 exemptions.
- Risk Factors: The New Warrants have extremely limited liquidity due to the lack of an established trading market and the Company's intent not to list them on any exchange.
Investor Verification Checklist
- Verify the final number of warrants exercised and New Warrants issued once the transaction closes on or about September 25, 2025.
- Confirm the net cash proceeds after deducting the $450,000 in fees and expenses payable to Newbridge Securities.
- Review the impact of the new warrant issuance on potential future dilution, noting the 5-year term and $0.84 exercise price.
- Monitor subsequent filings for any additional warrant inducement agreements mentioned by management.